WebApr 3, 2024 · Catherine Stehman-Breen, M.D., Dyne’s chief medical officer, held senior leadership roles at Amgen and Regeneron Pharmaceuticals, and most recently served … WebOct 4, 2024 · Dyne Therapeutics (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, visits ...
Dyne Therapeutics NasdaqGS:DYN Stock Report - Simply Wall St
WebNov 3, 2024 · Cash position: Cash, cash equivalents and marketable securities were $248.1 million as of September 30, 2024, which is anticipated to fund operations through 2024. Research and development (R&D) expenses: R&D expenses were $34.7 million for the quarter ended September 30, 2024, compared to $36.5 million for the quarter ended … WebThe 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Dyne Therapeutics Inc 50-day moving average is $12.61. smart builder solutions
$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks …
WebDyne Therapeutics Information. Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in ... WebFeb 9, 2024 · Glassdoor gives you an inside look at what it's like to work at Dyne Therapeutics, including salaries, reviews, office photos, and more. This is the Dyne … WebMay 16, 2024 · DYNE-101 is designed to enable targeted delivery to muscle tissue and address the genetic basis of the disease. The new data being presented during ASGCT … smart builders asheville